Read our latest interview to find out. Plus, EPKINLY® gets the green light from the US FDA for R/R follicular lymphoma
View in browser
OC logo 2018 CMYK

Newsletter

 18 July 2024 

_Call for Papers LB OC J HEP  (1)

Tackling cancer inequalities – the SAMBAI project

Discover how the SAMBAI project is using genomic, transcriptomic and bioinformatic approaches to create actionable public health strategies for overcoming cancer disparities.

 

READ MORE >>>

Jade OC NL feature image (2)-1
Jade NL mini images (7)

EPKINLY® approved by the US FDA for R/R follicular lymphoma

READ MORE >>>

Jade NL mini images (6)

Acupuncture may alleviate adverse effects of breast cancer hormone therapy

READ MORE >>>

 

Jade NL mini images (4)

Developing therapeutics to target oncogenic drivers of solid tumors in children

READ MORE >>>

 

JOURNAL ARTICLES

Targeting KRASG12C-mutated advanced colorectal cancer: research and clinical developments

This reviews the available clinical trial data on KRASG12C inhibitors in KRASG12C-mutated colorectal cancer, possible mechanisms of resistance to monotherapy, the research studying why available agents are proving to be less efficacious in colorectal cancer compared to NSCLC and future directions for these promising new drugs.

MORE >>>

Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer: a plain language summary of the DESTINY-Lung01 study

The DESTINY-Lung01 study includes 181 adults with metastatic NSCLC that could not be treated with surgery and who have had previous standard anticancer treatment. The publication includes information and results about 91 of the study participants who had HER2-mutant NSCLC. 

MORE >>>

Breaking the barriers of therapy resistance: harnessing ferroptosis for effective hepatocellular carcinoma therapy

This review presents a comprehensive overview of the crucial role played by ferroptosis in enhancing the efficacy of treatment for hepatocellular carcinoma. The main aim of this study is to examine the feasibility of utilizing ferroptosis as a therapeutic approach to improve the efficacy of hepatocellular carcinoma treatment and overcome drug resistance.

MORE >>>

Discover more journal content

Topics: Cancer biology and pathology | Clinical trials | Drug approvals | Drug development | Diagnostics | Epidemiology | Genetics and genomics | Immuno- oncology | Industry and business | Patient perspective | Personalized medicine | Preclinical research and trials | Prevention and screening | Targeted therapies |

Taylor & Francis Group, 2-4 Park Square, Milton Park, Abingdon, Oxfordshire OX14 4RN, United Kingdom

Manage preferences

Privacy Policy | Terms & Conditions

Facebook
LinkedIn
X-logo
Instagram
T&F-logo-2023-white-transparent

 

This is an email from Taylor & Francis Group. Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited and Taylor & Francis Group, LLC.

Taylor & Francis Group includes, but is not limited to: F1000 Research Ltd; Dove Press Ltd; and the publishing imprints of "Taylor & Francis", "Routledge", and "CRC Press". 

 

We respect your privacy and will not disclose, rent or sell your email address to advertisers without your consent. If you wish to unsubscribe, please click 'Manage preferences' above or write to the Data Privacy Manager, Taylor & Francis Group, 4 Park Square, Milton Park, Abingdon, OX14 4RN, UK. For more information, please review our Privacy Policy.

This email was sent to: